SBC Medical Group (SBC) to Release Earnings on Thursday

Key Points

• Q1 2026 results: SBC Medical Group will report before the market opens on Thursday, May 14 (earnings call 8:30 AM ET); analysts expect $0.10 EPS and $41.66M in revenue.
• Insider activity: CEO Yoshiyuki Aikawa sold 465,000 shares on April 28 for about $1.404M, insiders have sold roughly 7.99M shares in the past 90 days and still own 89.47% of the stock.
• Market snapshot and analyst view: The stock trades near $3.22 with a market cap of $330.31M and a P/E of 6.57; analysts are mixed (two Buys, one Sell) with an average price target of $8.50.

SBC Medical Group (NASDAQ:SBC - Get Free Report) is expected to be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect SBC Medical Group to post earnings of $0.10 per share and revenue of $41.6580 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its quarterly earnings data on Friday, March 27th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01. The firm had revenue of $39.57 million during the quarter, compared to the consensus estimate of $45.19 million. SBC Medical Group had a net margin of 29.37% and a return on equity of 20.76%. On average, analysts expect SBC Medical Group to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

SBC Medical Group Stock Performance

Shares of NASDAQ:SBC opened at $3.22 on Thursday. The company has a market cap of $330.31 million, a price-to-earnings ratio of 6.57 and a beta of 0.61. The company has a 50-day moving average price of $3.86 and a 200-day moving average price of $3.97. The company has a current ratio of 3.78, a quick ratio of 3.74 and a debt-to-equity ratio of 0.13. SBC Medical Group has a 12 month low of $2.97 and a 12 month high of $5.75.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. BTIG Research assumed coverage on shares of SBC Medical Group in a research note on Friday, March 6th. They set a "buy" rating and a $8.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of SBC Medical Group in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $8.50.

Insiders Place Their Bets

In other SBC Medical Group news, CEO Yoshiyuki Aikawa sold 465,000 shares of the company's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $3.02, for a total value of $1,404,300.00. Following the sale, the chief executive officer owned 78,839,460 shares in the company, valued at approximately $238,095,169.20. This represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 7,987,900 shares of company stock valued at $20,142,848 in the last 90 days. 89.47% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On SBC Medical Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN grew its holdings in SBC Medical Group by 195.1% in the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company's stock worth $54,000 after purchasing an additional 8,348 shares during the period. Russell Investments Group Ltd. grew its holdings in SBC Medical Group by 292.0% in the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company's stock worth $51,000 after purchasing an additional 8,771 shares during the period. Barclays PLC grew its holdings in SBC Medical Group by 123.7% in the fourth quarter. Barclays PLC now owns 17,779 shares of the company's stock worth $77,000 after purchasing an additional 9,831 shares during the period. Goldman Sachs Group Inc. purchased a new stake in SBC Medical Group in the fourth quarter worth about $49,000. Finally, Nuveen LLC purchased a new stake in SBC Medical Group in the fourth quarter worth about $53,000. Hedge funds and other institutional investors own 60.82% of the company's stock.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company's primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.